NP / PA
Doc-Aid Scribe Services, INC
Doc-Aid Scribe Services, INC was paid $4.81M by Medicaid between Jul 2020 and Dec 2024, across 37 billing codes. Its largest line is 87632, — 19% of everything it billed.
33Billing provider infoDOC-AID SCRIBE SERVICES, INC
LAREDO, TX 78045
LAREDO, TX 78045
33aNPI1275937641assigned 10/14/2014
33bProvider typeNurse Practitioner
28Total paid$4.81M
24GClaims117,495
24DCodes billed37
24AFirst – last monthJul 2020 – Dec 2024
Compared with peers
Next to other Nurse Practitioner providers in Texas
Rank by total paid#3 of 142
Median peer was paid$25K
This provider vs. median191×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,893 | $86K | |
| 2021 | 11,314 | $336K | |
| 2022 | 24,125 | $894K | |
| 2023 | 30,732 | $1.45M | |
| 2024incomplete | 48,431 | $2.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87632 | 19% | 5,071 | 4,731 | $903K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 17% | 2,662 | 2,393 | $802K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 12% | 13,202 | 11,063 | $555K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 15,584 | 13,254 | $499K |
| 87631 | 9.2% | 5,224 | 3,822 | $444K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 7.5% | 7,055 | 6,385 | $360K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 6.4% | 2,441 | 2,394 | $308K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4.4% | 17,777 | 15,439 | $210K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.8% | 3,671 | 3,278 | $135K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.1% | 5,228 | 4,616 | $99K |
| 99000 | 2.1% | 11,455 | 10,483 | $99K | |
| S8301 | Infection control supplies, not otherwise specified | 1.9% | 5,401 | 4,809 | $91K |
25 more codes
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.9% | 4,604 | $91K |
| 87486 | 1.3% | 2,644 | $62K | |
| 87581 | 1.3% | 2,642 | $62K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,285 | $39K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 378 | $16K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 101 | $8K |
| 86328 | <1% | 238 | $6K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 95 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 442 | $5K |
| 87807 | <1% | 431 | $4K | |
| 94760 | <1% | 1,900 | $2K | |
| 81002 | <1% | 423 | $1K | |
| 99051 | <1% | 3,631 | $463.14 | |
| 81025 | <1% | 55 | $368.73 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 39 | $264.78 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12 | $168.32 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 49 | $44.25 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 12 | $19.62 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 39 | $9.43 |
| A9150 | Non-prescription drugs | <1% | 333 | $2.98 |
| 99072 | 0% | 19 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 48 | $0.00 |
| 94664 | 0% | 12 | $0.00 | |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | 0% | 678 | $0.00 |
| 36416 | 0% | 614 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSAENZ, MONICA (CEO)